Jove
Visualize
Contact Us

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

302
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
302
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

402
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
402
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

357
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
357
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

183
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
183
Prevention of Further Absorption of Poison01:14

Prevention of Further Absorption of Poison

821
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
821
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

181
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coronavirus disease 2019 pneumonia with concomitant spontaneous pneumomediastinum, pneumothorax, and subcutaneous emphysema in a non-ventilated patient, complicated by pulmonary embolism: a case report.

Journal of medical case reports·2025
Same author

Development of Takotsubo cardiomyopathy following spontaneous coronary artery dissection in a patient with fibromuscular dysplasia.

BMJ case reports·2024
Same author

Protein interaction networks in the vasculature prioritize genes and pathways underlying coronary artery disease.

Communications biology·2024
Same author

Endothelial ARHGEF26 is an angiogenic factor promoting VEGF signalling.

Cardiovascular research·2021
Same author

Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease.

Nature genetics·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.4K

Hyperammonemic encephalopathy induced by valproic acid.

Qiuyu M Zhu1, Amitosh K Singh2, Huai-En Rachel Chang2

  • 1Internal Medicine, Kaiser Permanente Mid-Atlantic States, Gaithersburg, Maryland, USA martin.x.zhu@kp.org.

BMJ Case Reports
|February 13, 2024
PubMed
Summary
This summary is machine-generated.

Valproate (VPA) can cause hyperammonemic encephalopathy, a serious but less recognized side effect. Prompt treatment with lactulose and L-carnitine after VPA discontinuation led to a favorable outcome in a recent case.

Keywords:
Drugs: CNS (not psychiatric)Healthcare improvement and patient safetyPsychiatry (drugs and medicines)SafetyUnwanted effects / adverse reactions

More Related Videos

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

10.5K
Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.5K

Related Experiment Videos

Last Updated: Jul 3, 2025

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.4K
Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
09:37

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine

Published on: August 24, 2018

10.5K
Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain
08:23

Adaptation of Microelectrode Array Technology for the Study of Anesthesia-induced Neurotoxicity in the Intact Piglet Brain

Published on: May 12, 2018

9.5K

Area of Science:

  • Neurology
  • Pharmacology
  • Toxicology

Background:

  • Valproate (VPA) is a widely used antiepileptic medication with known severe adverse effects like hepatotoxicity and fetal risks.
  • These risks are highlighted by boxed warnings in the USA, emphasizing the need for careful patient monitoring.

Observation:

  • A case study involving a woman who developed hyperammonemic encephalopathy after starting VPA therapy is presented.
  • This specific adverse reaction, while less commonly known, can lead to significant patient morbidity.

Findings:

  • The patient experienced hyperammonemic encephalopathy attributed to VPA initiation.
  • Discontinuation of VPA and subsequent treatment with lactulose and L-carnitine resulted in a positive clinical outcome.

Implications:

  • This case highlights hyperammonemic encephalopathy as a critical, albeit underrecognized, adverse effect of Valproate therapy.
  • Early recognition and intervention, including drug cessation and specific treatments, are crucial for managing VPA-induced hyperammonemic encephalopathy and improving patient prognosis.